| 1 |
35396381 | Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia. | 2022 Apr 8 |
1 |
| 2 |
32266141 | NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation. | 2020 |
1 |
| 3 |
29949049 | Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation. | 2018 Oct |
1 |
| 4 |
27783203 | Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines. | 2017 Jul |
1 |
| 5 |
29054982 | Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration. | 2017 Dec |
1 |
| 6 |
26675378 | Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors. | 2016 Jan 12 |
1 |
| 7 |
25894564 | Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid. | 2015 Mar |
2 |
| 8 |
25201160 | NAMPT and NAPRT1: novel polymorphisms and distribution of variants between normal tissues and tumor samples. | 2014 Sep 9 |
1 |
| 9 |
24097869 | Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors. | 2013 Dec 15 |
1 |
| 10 |
24204194 | Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618. | 2013 Oct |
1 |
| 11 |
24403854 | Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models. | 2013 Dec |
1 |